Observation on the Efficacy of Edaravone Dexborneol in the Treatment of Large-area Cerebral Infarction
DOI:
https://doi.org/10.18063/apm.v10i2.886Keywords:
Edaravone dexborneol, Large-area cerebral infarction, mRS Score, NIHSS score, hs-CRP, PrognosisAbstract
Objective: To explore the efficacy and safety of edaravone dexborneol in the treatment of patients with large-area cerebral infarction by comparing the GCS score, mRS score, NIHSS score, BI score, and hs-CRP results before and after treatment, as well as the mRS score, mortality rate, length of hospital stay, and adverse reactions after 90 days of treatment between the two groups. Methods: A total of 102 patients with acute large-area cerebral infarction who were hospitalized in the neurology department of Shaanxi Provincial People’s Hospital from October 2020 to December 2021 were selected as the research subjects. All patients were randomly divided into an experimental group and a control group, with 51 patients in each group. The control group received conventional treatment, thrombolytic therapy, and endovascular interventional therapy, while the experimental group received additional edaravone dexborneol treatment for 14 days based on the above treatment methods. The GCS score, mRS score, NIHSS score, BI score, and hs-CRP results before and after treatment, as well as the mRS score, mortality rate, length of hospital stay, and adverse reactions after 90 days of treatment, were collected and statistically analyzed using SPSS 25.0. Results: The two groups were comparable at baseline, with no significant differences in demographics, laboratory parameters, stroke subtype (TOAST), neurological deficit (NIHSS), functional status (mRS, BI), consciousness (GCS), or inflammation (hs-CRP) (all P > 0.05). After 14 days of treatment, the experimental group demonstrated a significantly higher overall response rate (78.4% vs. 52.9%, P = 0.007), greater reduction in NIHSS score (P = 0.043) and greater increase in BI score (P = 0.017), while changes in GCS and mRS remained similar between groups (P > 0.05). Moreover, the experimental group achieved larger pre-to-post treatment improvements in NIHSS (P = 0.032) and BI (P = 0.013), but not in GCS or mRS (P > 0.05). Inflammatory marker hs-CRP decreased more markedly in the experimental group at day 14 and showed a greater change from baseline (both P < 0.001). By day 90, the experimental group exhibited lower mRS scores and greater mRS improvement than controls (P = 0.011 and P = 0.038, respectively), without differences in mortality (P > 0.05). Finally, there were no significant differences between groups in hospital length of stay or adverse event rates (P > 0.05), indicating both regimens were similarly safe and well tolerated. Conclusion: Edaravone dexborneol can effectively improve neurological deficits in patients with large-area cerebral infarction, improve patients’ quality of life, and has good safety. Edaravone dexborneol can improve inflammatory indicators in patients with large-area cerebral infarction, which is one of the mechanisms of edaravone dexborneol in the treatment of large-area cerebral infarction. Edaravone dexborneol can improve the short-term prognosis of patients with large-area cerebral infarction.
References
Zhou M, Wang H, Zhu J, et al., 2016, Cause-Specific Mortality for 240 Causes in China During 1990–2013: A Systematic Subnational Analysis for the Global Burden of Disease Study 2013. Lancet, 387(10015): 251–272.
Naghavi M, Abajobir A, Abbafati C, et al., 2017, Global, Regional, and National Age-Sex Specific Mortality for 264 Causes of Death, 1980–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet, 390(10100): 1151–1210.
Wang W, Jiang B, Sun H, et al., 2017, Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation, 135(8): 759–771.
Wang D, Liu J, Liu M, et al., 2017, Patterns of Stroke Between University Hospitals and Nonuniversity Hospitals in Mainland China: Prospective Multicenter Hospital-Based Registry Study. World Neurosurg, 98: 258–265.
Di Carlo A, 2009, Human and Economic Burden of Stroke. Age Ageing, 38(1): 4–5.
Hacke W, Schwab S, Horn M, et al., 1996, ‘Malignant’ Middle Cerebral Artery Territory Infarction: Clinical Course and Prognostic Signs. Arch Neurol, 53(4): 309–315.
Huttner H, Schwab S, 2009, Malignant Middle Cerebral Artery Infarction: Clinical Characteristics, Treatment Strategies, and Future Perspectives. Lancet Neurol, 8(10): 949–958.
Berrouschot J, Sterker M, Bettin S, et al., 1998, Mortality of Space-Occupying (‘Malignant’) Middle Cerebral Artery Infarction Under Conservative Intensive Care. Intensive Care Med, 24(6): 620–623.
Vahedi K, Vicaut E, Mateo J, et al., 2007, Sequential-Design, Multicenter, Randomized, Controlled Trial of Early Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction (DECIMAL Trial). Stroke, 38(9): 2506–2517.
Juttler E, Unterberg A, Woitzik J, et al., 2014, Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. N Engl J Med, 370(12): 1091–1100.
Group E A I S, 2003, Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction. Randomized, Placebo-Controlled, Double-Blind Study at Multicenters. Cerebrovasc Dis, 15(3): 222–229.
Zhang N, Komine-Kobayashi M, Tanaka R, et al., 2005, Edaravone Reduces Early Accumulation of Oxidative Products and Sequential Inflammatory Responses After Transient Focal Ischemia in Mice Brain. Stroke, 36(10): 2220–2225.
Shinohara Y, Yanagihara T, Abe K, et al., 2011, II. Cerebral Infarction/Transient Ischemic Attack (TIA). J Stroke Cerebrovasc Dis, 20(4 Suppl): S31–S73.
Wang Y, Liu M, Pu C, 2017, 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. Int J Stroke, 12(3): 302–320.
Liu R, Zhang L, Lan X, et al., 2011, Protection by Borneol on Cortical Neurons Against Oxygen-Glucose Deprivation/Reperfusion: Involvement of Anti-Oxidation and Anti-Inflammation Through Nuclear Transcription Factor KappaB Signaling Pathway. Neuroscience, 176: 408–419.
Almeida J R, Souza G R, Silva J C, et al., 2013, Borneol, a Bicyclic Monoterpene Alcohol, Reduces Nociceptive Behavior and Inflammatory Response in Mice. ScientificWorldJournal, 2013: 808460.
Zhang L, Feng Z, Chen R, et al., 2021, Study on the Efficacy of Alteplase Combined with Edaravone Dexborneol in the Treatment of Acute Ischemic Stroke. Smart Healthcare, 7(20): 133–135.
Jiang F, Wang D, 2022, Effects of Edaravone Dexborneol Combined with Urokinase Intravenous Thrombolysis on Serum Oxidative Stress Level, Carotid Intima-Media Thickness, and Serum Matrix Metalloproteinase-12 Level in Patients with Acute Cerebral Infarction Complicated with Diabetes. Shaanxi Medical Journal, 51(1): 88–91.
Chinese Guidelines for the Prevention and Treatment of Hypertension Revision Committee, Chinese Hypertension Alliance, Chinese Medical Association Cardiology Branch, Chinese Medical Doctor Association Hypertension Professional Committee, et al., 2019, Chinese Guidelines for the Prevention and Treatment of Hypertension (2018 Revision). Chinese Journal of Cardiology, 24(1): 24–56.
Li C, Zhou J, 2019, Interpretation of the 2019 ADA Standards of Medical Care in Diabetes. Chinese Medical Frontiers (Electronic Edition), 11(1): 66–74.
Joint Committee for the Revision of Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults, 2016, Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 Revision). Chinese Journal of Cardiology, 44(10): 833–853.
Li J, Zhang P, Wu S, et al., 2019, Stroke-Related Complications in Large Hemisphere Infarction: Incidence and Influence on Unfavorable Outcome. Ther Adv Neurol Disord, 12: 175628641983293.
Liu C, 2017, Discussion on the Clinical Characteristics and Treatment Measures of Large Area Cerebral Infarction. Chinese Journal of Modern Drug Application, 11(20): 45–46.
Xie H, Li Z, Sun H, et al., 2015, Application of New Treatment Options for Acute Massive Cerebral Infarction. Guangdong Medical Journal, 36(8): 1178–1181.
Jeon S B, Koh Y, Choi H A, et al., 2014, Critical Care for Patients with Massive Ischemic Stroke. J Stroke, 16(3): 146–160.
Li J, Zhang P, Wu S, et al., 2019, Stroke-Related Complications in Large Hemisphere Infarction: Incidence and Influence on Unfavorable Outcome. Ther Adv Neurol Disord, 12: 1278094832.
Xu J, Wang A, Meng X, et al., 2021, Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke, 52(3): 772–780.
Zhang Y, Jiang Y, Ren L, et al., 2021, Improvement Effect of Intravenous Infusion of Edaravone Dexborneol on Cerebral Injury in Patients with Acute Anterior Circulation Cerebral Infarction and Good Endovascular Treatment. Shandong Medical Journal, 61(18): 76–79.
Qin S, Li F, 2021, Progress in the Relationship Between Cerebral Infarction, hsCRP, and Carotid Atherosclerotic Plaque. Chinese Journal of Cardiovascular Rehabilitation Medicine, 30(2): 230–234.
Zahari S, Hanif E, Thambiah S, et al., 2021, High Sensitivity C-Reactive Protein (hsCRP): Its Relationship with Metabolic Syndrome and Framingham Risk Score. Malays J Pathol, 43(1): 33–40.
Lawler P, Bhatt D, Godoy L, et al., 2021, Targeting Cardiovascular Inflammation: Next Steps in Clinical Translation. Eur Heart J, 42(1): 113–131.
Xiong L, Yang X, Li F, 2022, Clinical Significance of Serum hs-CRP, PCT, and WBC in Patients with Lupus Nephritis and Urinary Tract Infection. Guizhou Medical Journal, 46(01): 33–34.
Yan J, Wang Y, Ni L, et al., 2008, Plasma High-Sensitivity C-Reactive Protein Level and Prognosis of Stroke. Chinese Journal of Neurology, 41(6): 376–380.
Yamamoto T, Yuki S, Watanabe T, et al., 1997, Delayed Neuronal Death Prevented by Inhibition of Increased Hydroxyl Radical Formation in Transient Cerebral Ischemia. Brain Res, 762(1–2): 240–242.
